I am still all in and planning to nibble and add at any bargains under $3-$4/share and I will hold dry powder for any swan dive should one happen (I would love to buy more under $1), but with a 40 share/day average volume for a year I just do not see a swan dive coming. I think every one but me and the insiders, sold long ago. My 5 year aveerage cost is about $5/share, so I am not selling for chump change, the CEO is not selling, annd the one other large shareholder is holding, and the ex CEO has never sold either.
OS is only 13 Mil shares with the CEO owning nealry 8 million of them, and the pre R/M pre R/S group that did a convertible loan about 2 years ago, holding the rest (other than my shares) at a cost of IIRC .25/share, but they have never sold a single share, so they must be planning to move this $20/share and raise serious cash someday to fund it like all other real biotechs.
With last months news of an issued patent for the new cancer drug, this could be the year STLT moves to an all time high and gets noticed.
I love the new CEOs business plan, and his execution so far of buying Celtic Biotech so cheap. The plan is to buy up millions of dollars of Federally funded R&D that is stuck parked on University shelves (Universities have no idea how to get their completed R&D to market), for chump change, then incubate them like Celtic Biotech and spin them off as new IPOs. Kinda like Goldsachs....and the new CEO has the skilll set and know how to do this.
